SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001144204-17-025639
Filing Date
2017-05-09
Accepted
2017-05-09 16:26:40
Documents
6
Period of Report
2017-05-09
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K v466501_8k.htm 8-K 18496
2 EXHIBIT 99.1 v466501_ex99-1.htm EX-99.1 117140
3 EXHIBIT 99.2 v466501_ex99-2.htm EX-99.2 5644
4 GRAPHIC image_001.jpg GRAPHIC 51553
5 GRAPHIC image_002.jpg GRAPHIC 199778
6 GRAPHIC image_003.jpg GRAPHIC 142182
  Complete submission text file 0001144204-17-025639.txt   684745
Mailing Address UGLAND HOUSE, SOUTH CHURCH STREET GEORGE TOWN, GRAND CAYMAN E9 KY1-1104
Business Address UGLAND HOUSE, SOUTH CHURCH STREET GEORGE TOWN, GRAND CAYMAN E9 KY1-1104 650-808-6000
Theravance Biopharma, Inc. (Filer) CIK: 0001583107 (see all company filings)

IRS No.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36033 | Film No.: 17826799
SIC: 2834 Pharmaceutical Preparations